Author:
Warwick Anne B.,Malempati Suman,Krailo Mark,Melemed Allen,Gorlick Richard,Ames Matthew M.,Safgren Stephanie L.,Adamson Peter C.,Blaney Susan M.
Funder
Eli Lilly and Company, and National Cancer Institute
Subject
Oncology,Hematology,Pediatrics, Perinatology, and Child Health
Reference30 articles.
1. Pemetrexed: A multitargeted antifolate (ALIMTA, LY-231514);Jones;Expert Rev Anticancer Ther,2002
2. Review of a promising new agent-Pemetrexed disodium;Paz-Ares;Cancer,2003
3. FDA drug approval summaries: Pemetrexed (Alimta);Hazarika;Oncologist,2004
4. Ly231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes;Shih;Cancer Res,1997
5. Enzyme inhibition, polyglutamation, and the effect of LY 231514 (MTA) on purine biosynthesis;Mendelsohn;Semin Oncol,1999
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献